{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:55:05Z","timestamp":1761155705347},"reference-count":30,"publisher":"Wiley","issue":"3pt2","license":[{"start":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T00:00:00Z","timestamp":1374710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2014,3]]},"abstract":"Background<\/jats:title>The cost\u2010effectiveness of the donor health questionnaire (DHQ<\/jats:styled-content>) as a tool to assess donor eligibility has not been quantified. This study focused on cost\u2010effectiveness of the DHQ<\/jats:styled-content> in preventing transfusion\u2010transmitted infections (TTI<\/jats:styled-content>s).<\/jats:p><\/jats:sec>Study Design and Methods<\/jats:title>Data on whole blood donor eligibility assessments in the N<\/jats:styled-content>etherlands in 2008 to 2010 were analyzed. Based on test results and epidemiologic data on TTIs<\/jats:styled-content>, the number of donor visits in their window phase was calculated. Subsequently, the incremental cost\u2010effectiveness ratio (ICER<\/jats:styled-content>) of the DHQ<\/jats:styled-content> was calculated.<\/jats:p><\/jats:sec>Results<\/jats:title>The overall annual deferral rate in the study period was 9.6% (9.3%\u201010.0%). The annual deferral rate for TTI<\/jats:styled-content> risk was 0.86% (0.82%\u20100.89%). Taking into account the number of self\u2010deferrals, deferral rate for TTI<\/jats:styled-content> risk in all donors was 1.90% (1.81%\u20102.02%). The calculated annual numbers of prevented cases of TTI<\/jats:styled-content> were hepatitis B<\/jats:styled-content>, 0.142; hepatitis C<\/jats:styled-content>, 0.010; human immunodeficiency virus, 0.016; and syphilis, 0.135. The annual costs for TTI<\/jats:styled-content> risk\u2013related eligibility assessments, deferrals, and substitutions were \u20ac84,807 (\u20ac55,193\u2010\u20ac123,811) for the blood establishment (BE<\/jats:styled-content>) and \u20ac90,501 (\u20ac46,965\u2010\u20ac159,571) for deferred donors. Annual savings were \u20ac991 (\u20ac276\u2010\u20ac2325), while annual quality\u2010adjusted life\u2010years (QALYs<\/jats:styled-content>) gained were 0.120 (0.059\u20100.226). Hence, the ICER<\/jats:styled-content> for the DHQ<\/jats:styled-content> on preventing TTI<\/jats:styled-content>s was \u20ac696,744 (\u20ac315,422\u2010\u20ac1,611,681) for BE<\/jats:styled-content> costs only and \u20ac1,449,055 (\u20ac669,439\u2010\u20ac3,145,961) including costs for deferred donors.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The DHQ<\/jats:styled-content> enhances self\u2010selection and should not be abandoned. However, the DHQ<\/jats:styled-content> is not a cost\u2010effective tool for further reducing TTI<\/jats:styled-content>s. The high costs per case prevented and the small number of QALY<\/jats:styled-content>s gained argue against maintaining deferral policy through the DHQ<\/jats:styled-content> at the current level.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.12349","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T17:16:51Z","timestamp":1374772611000},"page":"879-888","source":"Crossref","is-referenced-by-count":15,"title":["Cost\u2010effectiveness of questionnaires in preventing transfusion\u2010transmitted infections"],"prefix":"10.1111","volume":"54","author":[{"given":"Wim","family":"de Kort","sequence":"first","affiliation":[{"name":"Sanquin Blood Supply Foundation Nijmegen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"van den Burg","sequence":"additional","affiliation":[{"name":"Sanquin Blood Supply Foundation Nijmegen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Geerligs","sequence":"additional","affiliation":[{"name":"Sanquin Blood Supply Foundation Nijmegen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieternel","family":"Pasker\u2010de Jong","sequence":"additional","affiliation":[{"name":"Sanquin Blood Supply Foundation Nijmegen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanneke","family":"Marijt\u2010van der Kreek","sequence":"additional","affiliation":[{"name":"Sanquin Blood Supply Foundation Nijmegen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,25]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Rijks Instituut voor Volksgezondheid en Milieu (RIVM).Infectieziekte\u2010informatie voor professionals. RIVM Bilthoven the Netherlands.2012. [cited 2013 Feb 1]. Available from: URL:http:\/\/www.rivm.nl\/Onderwerpen\/Onderwerpen\/I\/Infectieziekte_informatie_voor_professionals"},{"key":"e_1_2_8_3_1","unstructured":"Rijks Instituut voor Volksgezondheid en Milieu (RIVM).Hepatitis B. RIVM Bilthoven the Netherlands.2012. [cited 2013 Feb 1]. Available from: URL:http:\/\/www.rivm.nl\/Onderwerpen\/Ziekten_Aandoeningen\/H\/Hepatitis_B"},{"key":"e_1_2_8_4_1","unstructured":"Rijks Instituut voor Volksgezondheid en Milieu (RIVM).LCI\u2010richtlijn hepatitis C. RIVM Bilthoven the Netherlands.2012. [cited 2013 Feb 1]. Available from: URL:http:\/\/www.rivm.nl\/Bibliotheek\/Professioneel_Praktisch\/Richtlijnen\/Infectieziekten\/LCI_richtlijnen\/LCI_richtlijn_Hepatitis_C"},{"key":"e_1_2_8_5_1","unstructured":"Rijks Instituut voor Volksgezondheid en Milieu (RIVM).Hiv infectie. RIVM Bilthoven the Netherlands.2012. [cited 2013 Feb 1]. Available from: URL:http:\/\/www.rivm.nl\/Onderwerpen\/Ziekten_Aandoeningen\/H\/Hiv_infectie"},{"key":"e_1_2_8_6_1","unstructured":"Rijks Instituut voor Volksgezondheid en Milieu (RIVM).Syfilis. RIVM Bilthoven the Netherlands.2012. [cited 2013 Feb 1]. Available from: URL:http:\/\/www.rivm.nl\/Onderwerpen\/Ziekten_Aandoeningen\/S\/Syfilis"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02881.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38298193102.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01903.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335581"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2007.03.002"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.01048.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02037.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.01008.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2011.07.001"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540360035027"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41121480.x"},{"key":"e_1_2_8_18_1","unstructured":"Raad voor de Volksgezondheid en Zorg.Advies zinnige en duurzame zorg. Zoetermeer the Netherlands;2006."},{"key":"e_1_2_8_19_1","volume-title":"Making choices in health: WHO guide to cost\u2010effectiveness analysis","author":"Tan\u2010Torres Edejer E","year":"2003"},{"key":"e_1_2_8_20_1","unstructured":"WHO.Information on the threshold values used in CHOICE analyses for the relative cost\u2010effectiveness of an intervention.2013. [cited 2013 May 1]. Available from: URL:http:\/\/www.who.int\/choice\/costs\/CER_thresholds\/en\/print.html"},{"key":"e_1_2_8_21_1","volume-title":"Principles for the development of NICE guidance","author":"National Institute for Health and Clinical Excellence","year":"2005"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04160.x"},{"key":"e_1_2_8_23_1","unstructured":"Stichting Loonwijzer.Minimum looncheck: uurloon\u2014juli 2013.2013. [cited 2012 Dec 15]. Available from: URL:http:\/\/www.loonwijzer.nl\/home\/minimumlooncheck\/minimum\u2010looncheck\u2010uurloon"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03319.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01378.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01881.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2003.00660.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03400.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/oem.54.1.1"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01129.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2824.2010.01373.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.12349","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.12349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:39:23Z","timestamp":1694630363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.12349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,25]]},"references-count":30,"journal-issue":{"issue":"3pt2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/trf.12349"],"URL":"https:\/\/doi.org\/10.1111\/trf.12349","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,25]]}}}